Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Feb 15, 2011 (Vol. 31, No. 4)

IDBS Set to Optimize Bioprocesses at Lonza

Data-Management and Execution System Will Be Used to Manage Mammallian Cell Culture Data

  • Data-Management Technology

    “BPES is based upon IDBS’ data-management technology,” noted Kipling, adding that it is a solution that can be rapidly deployed to streamline and optimize bioprocess workflows.

    “This allows data to be stored in context and more effectively shared between groups, deployed as a source of corporate knowledge, and used to monitor and improve process development and biological production operations,” he said.

    According to Kipling, this solution enables organizations to:

    • lessen the amount of repeated work by more than 10% with better access to current and past data and knowledge;

    • reduce unnecessary load on fixed capital assets;

    • speed up development, technology transfer and continuous improvement;

    • troubleshoot processes and perform root-cause analysis in minutes rather than weeks;

    • implement a knowledge and data management platform to support ICH Q10, QbD, and process understanding;

    • compare data and perform process intelligence queries to help improve and optimize processes;

    • trace and optimize component usage and equipment performance; and,

    • dramatically reduce the time assiciated with technology transfer.

    Lonza officials said that it was because of these advantages and capabilities that they chose the IDBS system.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »